We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Twist Bioscience, Distributed Bio Partner

News   Oct 13, 2016

 
Twist Bioscience, Distributed Bio Partner
 
 
 

RELATED ARTICLES

Miscarriage Cause and Key Cellular Targets of Potential Drugs Uncovered

News

Tragic miscarriages for a couple have led to a discovery with potentially broad implications for future disease treatments, according to a team of researchers at the University of North Carolina School of Medicine.

READ MORE

HIV Therapy Reduces Virus and Boosts Immunity in Drug-Resistant Patients

News

A new HIV drug reduced viral replication and increased immune cells in individuals with advanced, drug-resistant HIV infection. Used in combination with existing HIV medications, the drug is a promising strategy for patients who have run out of effective treatment options.

READ MORE

Rockland Immunochemicals, Inc. CSO Opines “Benefits of Polyclonal Antibodies” in Peer-reviewed Article

News

Dr. Carl Ascoli, Chief Science Officer at Rockland, and Dr. Birte Aggeler, Director of Antibody Development at Bio-Techne, have composed a review article on the pros and cons of polyclonal, conventional monoclonal, and recombinant monoclonal antibodies.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE